Endometrial Neoplasms
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
Subtype terms (2)
More specific conditions that are subtypes of Endometrial Neoplasms in the MeSH hierarchy.
- Carcinoma, Endometrioid
21 drugs (15 approved, 6 experimental)
- Endometrial Stromal Tumors
1 drug approved
Drugs by status
Approved for this indication (2)
Phase 4 trials (21)
Phase 3 trials (60)
- cetirizine
- sodium chloride
- conjugated equine estrogens
- anlotinib
- Filgrastim
- atezolizumab
- datopotamab deruxtecan
- lutropin alpha
- hyaluronidase (human recombinant)
- fam-trastuzumab deruxtecan-nxki
- oteracil
- paclitaxel
- metformin
- ifosfamide
- octreotide
- ixabepilone
- epirubicin
- pyridoxine
- carboplatin
- navtemadlin
- sacituzumab govitecan
- bnt323
- Lerociclib
- sargramostim
- fruquintinib
- letrozole
- durvalumab
- cyproviron
- gimeracil
- misoprostol
- +30 more
Phase 2 trials (258)
- mgi-114
- platelet-rich plasma
- erlotinib
- epacadostat
- selinexor
- capecitabine
- vibostolimab
- topotecan
- phosphatidylcholine
- vls-1488
- Belzutifan
- trametinib
- dendritic cells
- syd985
- bi-2536
- azd5305
- zalypsis
- hs-20089
- rosuvastatin
- aflibercept
- trastuzumab emtansine
- uprosertib
- cdx-1140
- irosustat
- norethindrone
- triptorelin
- arsenic trioxide
- vistusertib
- ciprofloxacin
- afuresertib
- +228 more
Phase 1 trials (125)
- imlunestrant
- bl-m17d1
- prt3645
- coti2
- bl-m07d1
- torl-1-23
- vinorelbine
- nm32-2668
- cpi-006
- lncb74
- mgc026
- alta2618
- vsv-hifnbeta-nis
- pf-07224826
- seclidemstat
- xl092
- 7-hydroxystaurosporine
- nkt3447
- atv-1601
- ao-252
- pf-07260437
- personalized neoantigen vaccine
- atx-559
- pertscan-99m
- almond
- veliparib
- itacitinib
- agen1181
- nrm-823
- naptumomab estafenatox
- +95 more
Other trials (21)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (65)
- Eisai
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- AEterna Zentaris
- Karyopharm Therapeutics Inc
- R-Pharm
- Tesaro
- National Cancer Institute (NCI)
- National Cancer Institute, France
- Huazhong University of Science and Technology
- University of Arizona
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cancer Research UK
- University of London
- Ciusss de L'Est de l'Île de Montréal
- Cornell University
- Harvard University
- Danish Gynecological Cancer Group
- Eastern Cooperative Oncology Group
- Gynecologic Oncology Group
- Indiana University
- Institut de Cancérologie de Lorraine
- Institut National de la Santé Et de la Recherche Médicale, France
- Katholieke Universiteit Leuven
- Lund University
- NRG Oncology
- New York University
- +35 more
Organization Involved with Phase 2 Indications (158)
- Kevelt AS
- Incyte
- Ability Pharmaceuticals SL
- Regeneron
- Daiichi Sankyo
- Foundation Medicine
- Cephalon
- Millennium Pharmaceuticals
- Clovis Oncology
- Genmab
- Advenchen Laboratories, LLC
- Astellas
- Immunomedics
- Medivation
- Exelixis
- Genentech
- Genzyme
- Pfizer
- Sanofi
- Ipsen
- Novartis
- Ariad Pharmaceuticals
- Union Therapeutics
- CASI Pharmaceuticals, Inc.
- Esperas Pharma Inc.
- Endocyte
- GlaxoSmithKline
- Gradalis, Inc.
- Hengrui Therapeutics, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- +128 more
Organization Involved with Phase 1 Indications (37)
- Abbott
- AbbVie
- Roche
- Wyeth
- ArQule
- Atara Biotherapeutics
- Bio-Path Holdings, Inc.
- Corvus Pharmaceuticals, Inc.
- Merrimack Pharmaceuticals
- ShangHai HaiHe Pharmaceutical
- Berg, LLC
- National Institutes of Health (NIH)
- Oncology Institute of Southern Switzerland
- Cedars-Sinai Medical Center
- Duke University
- HonorHealth Research Institute
- Rutgers University
- University of South Florida
- University of Virginia
- Jiao Tong University
- Xencor
- Fortress Biotech
- SCRI Development Innovations
- MannKind Corp
- Ospedale S. Giovanni Bellinzona
- University of Western Ontario
- ICON
- Novotech
- American Cancer Society, Inc.
- Government of Poland
- +7 more
Organization Involved with Other Experimental Indications (6)